Guardant Health, Inc. is a precision oncology company that develops blood and tissue-based tests for cancer screening, monitoring, and treatment selection. The company's product portfolio includes the Guardant360 CDx and Guardant360 Liquid tests for therapy selection in advanced solid tumors, the Guardant Reveal test for minimal residual disease detection and therapy response monitoring, and the Shield blood test for primary colorectal cancer screening. Guardant Health also offers the Guardant360 Tissue test for multiomics analysis and the GuardantINFINITY and GuardantOMNI blood tests for biopharmaceutical research. The company utilizes its Smart Platform, which integrates methylation technology with genomic, epigenomic, and RNA-based data, along with the InfinityAI learning engine. Guardant Health serves oncologists, primary care clinicians, and biopharmaceutical companies in the United States and globally. It collaborates with partners in Europe and Asia to expand commercial access and provides data through the GuardantINFORM platform to support drug development.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Diagnostics & Research Homepage guardanthealth.com
Sector Healthcare IR page investors.guardanthealth.com/overview/default.aspx
Tags
precision oncology, liquid biopsy, cancer screening, minimal residual disease, companion diagnostics, genomic testing, epigenomics, biomarker discovery, tumor mutation profiling, multi-cancer detection, Guardant360 CDx, Guardant360 Liquid, Guardant Reveal, Guardant360 Tissue, Shield, GuardantINFINITY, GuardantOMNI, GuardantINFORM, Smart Platform, InfinityAI
Press page guardanthealth.com/newsroom/press-releases

Metrics

Valuation  
Market cap $ 20.149B
Market cap (USD) $ 20.149B
P/E -40.53
PEG —
P/BV -73.03
P/S 15.75
P/OCF -116.14
P/FCF -86.79
Dividend yield —
Turnover / mcap —
Returns  
ROE 419.2%
ROI -29.6%
ROIC -23.3%
Profit margin -42.4%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding Yes
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 38
Quality score -11.1%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017
Revenue 982.021M 739.016M 563.948M 449.538M 373.653M 286.73M 214.375M 90.639M 49.842M
Net profit -416.277M -436.373M -479.449M -654.588M -384.77M -246.283M -75.651M -85.063M -83.221M
Free cash flow -233.066M -274.943M -345.461M -386.924M -284.052M -140.1M -65.851M -92.388M -78.916M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017
Share price 102.14 30.55 27.05 27.2 100.02 128.88 78.14 37.59 —
Price performance 12m 2.34 0.13 -0.01 -0.73 -0.22 0.65 1.08 — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) — 12.8M 35.7M 48M 53.3M 97.7M 97.3M 88.8M 110M 138M
↳ YoY growth +179.1% +34.5% +11.1% +83.2% -0.4% -8.7% +24.2% +25.0%
↳ 5y CAGR +50.0% +20.0% +18.1% +20.9%
Lease liabilities (USD) — — 0.00 40.4M 48.2M 239M 232M 214M 194M 206M
Cash and deposits (USD) 33.6M 72.3M 141M 143M 833M 492M 142M 1.13B 526M 378M
Intangible assets (USD) — — 7.8M 8.52M 16.2M 14.2M 11.7M 8.98M 6.76M 25.9M
Right-of-use assets (USD) — — 14.5M 29.1M 37.3M 189M 174M 158M 142M 159M
Cash flow detail
Operating cash flow (USD) -36.7M -72.2M -72.2M -47.1M -104M -209M -309M -325M -240M -185M
Purchases of property, plant and equipment (USD) -1.77M -6.68M -20.2M -18.7M -36.2M -75M -77.5M -20.5M -35.1M -48.3M
Purchases of intangible assets (USD) 0.00 -2.3M 0.00 -2.5M -17.9M 0.00 0.00 — — —
Change in receivables (cash effect) (USD) -2.79M -9.29M -22.9M -7.39M -5.46M -44.4M 375,000 8.38M -21.4M -28.2M
Change in inventories (cash effect) (USD) -351,000 -4.52M -1.85M -6.05M -7.54M -7.96M -20.9M -10.4M -9.14M -14.8M
Change in payables (cash effect) (USD) 2.15M 1.25M 5.05M 4.34M -7.86M 8.64M — — — —
Share buybacks (cash effect) (USD) -100,000 -7.22M -172,000 0.00 0.00 — — 0.00 0.00 -45M
Interest paid (cash effect) (USD) -2.24M -1.34M -1.25M -1.18M 0.00 0.00 — 0.00 0.00 -3.77M
Income taxes paid (cash effect) (USD) -14,000 -26,000 -102,000 -298,000 -331,000 -393,000 -1.33M -1.97M -1.01M -869,000
Share-based compensation (USD) 1.97M 3.67M 6.85M 17M 144M 151M 94.7M 90.8M 140M 166M
Operating cash flow before change in receivables (USD) -33.9M -62.9M -49.3M -39.7M -98.5M -165M -310M -333M -218M -157M
Free cash flow (OCF - PPE - intangibles) (USD) -38.5M -81.2M -92.4M -68.4M -158M -284M -387M -345M -275M -233M
Income detail
Research and development expense (USD) 10.9M 25.6M 50.7M 86.3M 150M 263M 374M 367M 348M 364M
↳ 5y CAGR +89.2% +71.0% +48.6% +32.1% +19.4%
Total comprehensive income (USD) -46.2M -83.7M -83.8M -66.7M -245M -392M -669M -464M -438M -416M
Comprehensive income to owners (USD) -46.2M -83.7M -84.6M -74.5M -252M -413M -669M -464M -438M -416M
Reported Mar 19, 2019 Mar 19, 2019 Mar 2, 2020 Mar 2, 2020 Feb 25, 2021 Feb 24, 2022 Feb 23, 2023 Feb 19, 2026 Feb 19, 2026 Feb 19, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

PALO ALTO, Calif. November 11, 2026—(BUSINESS WIRE)—Guardant Health, Inc. (“Guardant Health”) (Nasdaq: GH), a leading precision oncology company, today announced its intention to offer $500.0 million aggregate principal amount of convertible senior notes due 2032 (the “notes”) in a private offering (the “offering”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Guardant Health also intends to grant the initial purchasers of the notes an option to purchase, for settlement within a period of 13 days from, and including, the date the notes are first issued, up to an additional $50.0 million aggregate principal amount of notes. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

The notes will be senior, unsecured obligations of Guardant Health, will accrue interest payable semi-annually in arrears and will mature on May 15, 2032, unless earlier converted, redeemed or repurchased by Guardant Health.

On November 5, 2026, Guardant Health, Inc. (the “Company”) issued a press release announcing financial results for the fiscal quarter ended September 30, 2026. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

November 5, 2026

Third quarter 2026 revenue growth of 36% driven by strong performance in Oncology and Screening

Raises 2026 revenue guidance to $1.36 to $1.37 billion, representing growth of 38% to 40%

PALO ALTO, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter ended September 30, 2026.

Third Quarter 2026 Financial Highlights

For the three-month period ended September 30, 2026, as compared to the same period of 2025:

  • Reported total revenue of $361.0 million, an increase of 36%, driven by:
    • Oncology revenue of $231.3 million, an increase of 25%, and 117,000 oncology tests, an increase of 58%
    • Biopharma & Data revenue of $59.0 million, an increase of 8%
    • Screening revenue of $67.6 million, an increase of 180%, and 83,000 Shield tests, an increase of 246%
  • Generated non-GAAP gross margin of 67%, compared to 66% for the third quarter of 2025

Recent Operating Highlights

  • Received U.S. Food and Drug Administration (FDA) approval and CE-marking in Europe for Guardant360 CDx as a companion diagnostic for AstraZeneca’s ETCAMAH (camizestrant), the first FDA approval of a liquid biopsy companion diagnostic for longitudinal testing in breast cancer
  • Received FDA approval for Guardant360 CDx as a companion diagnostic for INLURIYO (imlunestrant) in combination with VERZENIO (abemaciclib) for eligible patients with ESR1-mutated advanced or metastatic breast cancer
  • Submitted a premarket approval (PMA) application to the FDA for Guardant360 Tissue
  • Launched Guardant Reveal Ultra with biopharma partners and remain on track for clinical launch in 2026
  • Expanded commercial coverage for Shield to more than 80% of eligible lives, with key additions including UnitedHealth Group, Carelon Healthcare Services, and EviCore
  • Successfully deployed the new FDA-approved lower COGS, higher-throughput Shield workflow

“Revenue grew 36% year over year as we continued to execute across Oncology, Screening, and Biopharma,” said Helmy Eltoukhy, co-founder and co-CEO. “Oncology volume grew 58% with broad contributions across our portfolio. The FDA approval of Guardant360 CDx for longitudinal ESR1 testing is a major advance for breast cancer patients, ushering in a new paradigm of cancer treatment. It reinforces the role of Guardant360 in enabling earlier therapy decisions and strengthens our leadership across the cancer care continuum.”

“Shield continued to build momentum in the third quarter, with volume more than tripling year over year to 83,000 tests,” said AmirAli Talasaz, co-founder and co-CEO. “Commercial coverage continues to expand, with recent policy updates extending Shield coverage to approximately 100 million lives. With our lower COGS, higher-throughput workflow now fully implemented, we have a strong operational foundation to meet future Shield demand. Together, these advances expand access to Shield and move us closer to making blood-based cancer screening a routine part of preventive care.”

Third Quarter 2026 Financial Results

Revenue was $361.0 million for the third quarter of 2026, a 36% increase from $265.2 million for the corresponding prior year period. Oncology revenue grew 25% to $231.3 million for the third quarter of 2026, from $184.4 million for the corresponding prior year period, driven primarily by an increase in Oncology test volume, which grew 58% over the prior year period. Screening revenue grew 180% to $67.6 million for the third quarter of 2026, from $24.1 million for the corresponding prior year period, driven primarily by an increase in Shield test volume, which grew to 83,000 tests in the third quarter of 2026, from 24,000 tests in the prior year period. Biopharma & Data revenue grew 8% to $59.0 million for the third quarter of 2026, from $54.7 million for the corresponding prior year period. Licensing and other revenue was $3.1 million for the third quarter of 2026, compared to $2.0 million for the corresponding prior year period.

Gross profit, or total revenue less cost of revenue, was $236.2 million for the third quarter of 2026, an increase of $64.5 million or 38%, from $171.6 million for the corresponding prior year period. Gross margin, or gross profit divided by total revenue, was 65% for the third quarter of 2026, as compared to 65% for the corresponding prior year period.

Non-GAAP gross profit was $240.2 million for the third quarter of 2026, an increase of $65.9 million or 38%, from $174.3 million for the corresponding prior year period. Non-GAAP gross margin was 67% for the third quarter of 2026, as compared to 66% for the corresponding prior year period.

Operating expenses were $368.9 million for the third quarter of 2026, as compared to $270.6 million for the corresponding prior year period. The year-over-year increase in operating expenses was primarily related to commercial infrastructure expansion and marketing activities to support Screening and Oncology growth and an increase in stock-based compensation. Non-GAAP operating expenses were $287.4 million for the third quarter of 2026, as compared to $228.9 million for the corresponding prior year period. The year-over-year increase in non-GAAP operating expenses was primarily related to commercial infrastructure expansion and marketing activities to support Screening and Oncology growth.

Net loss was $124.4 million for the third quarter of 2026, as compared to $92.7 million for the corresponding prior year period. Net loss per share was $0.93 for the third quarter of 2026, as compared to $0.74 for the corresponding prior year period.

Non-GAAP net loss was $38.8 million for the third quarter of 2026, as compared to $48.3 million for the corresponding prior year period. Non-GAAP net loss per share was $0.29 for the third quarter of 2026, as compared to $0.39 for the corresponding prior year period.

Adjusted EBITDA loss was $37.3 million for the third quarter of 2026, as compared to a $45.5 million loss for the corresponding prior year period.

Free cash flow for the third quarter of 2026 was $(37.2) million, as compared to $(45.8) million for the corresponding prior year period.

Cash, cash equivalents, and restricted cash were $1.1 billion as of September 30, 2026.

2026 Guidance

Guardant Health now expects full year 2026 revenue to be in the range of $1.36 to $1.37 billion, representing growth of 38% to 40% compared to full year 2025. This compares to the prior range of $1.34 to $1.36 billion, representing growth of 36% to 38%.

Within this revenue range:

  • Oncology revenue is expected to grow approximately 30% and Oncology volume is now expected to grow over 50%.
  • Biopharma & Data revenue growth is expected to be in the low double-digit range.
  • Screening revenue is now expected to be in the range of $233 to $238 million, driven by Shield volume of 285,000 to 290,000 tests. This compares to the prior guidance of $218 to $230 million revenue and 270,000 to 285,000 tests.

Guardant Health now expects full year 2026 non-GAAP gross margin to be 65%, compared to prior guidance of 64% to 65%. The company expects total non-GAAP operating expenses to be in the range of $1.105 to $1.125 billion, an increase compared to the prior range of $1.080 to $1.100 billion. Guardant Health now expects full-year free cash flow burn of $205 million to $220 million, compared to the previous outlook of $195 million to $205 million.

Webcast Information

Guardant Health will host a conference call to discuss the third quarter 2026 financial results after market close on Thursday, November 5, 2026 at 1:30 pm Pacific Time / 4:30 pm Eastern Time. A webcast of the conference call can be accessed at http://investors.guardanthealth.com . The webcast will be archived and available for replay for at least 90 days after the event.

Non-GAAP Measures

Guardant Health has presented in this release certain financial information in accordance with U.S. Generally Accepted Accounting Principles (GAAP) and also on a non-GAAP basis, including non-GAAP cost of revenue, non-GAAP gross profit, non-GAAP research and development expense, non-GAAP sales and marketing expense, non-GAAP general and administrative expense, non-GAAP loss from operations, non-GAAP net loss, non-GAAP net loss per share, basic and diluted, adjusted EBITDA, and free cash flow.

We define our non-GAAP measures as the applicable GAAP measure adjusted for the impacts of stock-based compensation and related employer payroll tax expense, amortization of intangible assets, impairment of non-marketable equity securities, gain on extinguishment of convertible notes, and other items, including contingent consideration and non-recurring legal expenses.

Adjusted EBITDA is defined as net loss adjusted for interest income; interest expense; other income (expense), net; provision for income taxes; depreciation and amortization expense; stock-based compensation expense and related employer payroll tax expense; and other items, including contingent consideration and non-recurring legal expenses. Free cash flow is defined as net cash used in operating activities in the period less purchases of property and equipment in the period.

We believe that the exclusion of certain income and expenses in calculating these non-GAAP financial measures can provide a useful measure for investors when comparing our period-to-period core operating results, and when comparing those same results to that published by our peers. We exclude certain items because we believe that these income and expenses do not reflect expected future operating performance. Additionally, certain items are inconsistent in amounts and frequency, making it difficult to perform a meaningful evaluation of our current or past operating performance. We use these non-GAAP financial measures to evaluate ongoing operations, for internal planning and forecasting purposes, and to manage our business.

These non-GAAP financial measures are not intended to be considered in isolation from, as substitute for, or as superior to, the corresponding financial measures prepared in accordance with GAAP. There are limitations inherent in non-GAAP financial measures because they exclude charges and credits that are required to be included in a GAAP presentation, and do not present the full measure of our recorded costs against its revenue. In addition, our definition of the non-GAAP financial measures may differ from non-GAAP measures used by other companies.

About Guardant Health

Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For more information, visit guardanthealth.com and follow the company on LinkedIn, X (Twitter) and Facebook.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health’s liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health’s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2025, and in its other reports filed with or furnished to the Securities and Exchange Commission thereafter. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health’s views as of any date subsequent to the date of this press release.

Guardant Health, Inc.Condensed Consolidated Statements of Operations(unaudited)(in thousands, except per share data)
Three Months Ended September 30, Nine Months Ended September 30,
2026 2025 2026 2025
Revenue $ 360,975 $ 265,196 $ 997,618 $ 700,755
Costs and operating expenses:
Cost of revenue 124,822 93,587 345,690 249,515
Research and development expense 100,838 89,957 288,409 265,927
Sales and marketing expense 177,218 127,375 536,304 351,279
General and administrative expense 90,862 53,266 210,448 150,477
Total costs and operating expenses 493,740 364,185 1,380,851 1,017,198
Loss from operations (132,765 ) (98,989 ) (383,233 ) (316,443 )
Interest income 9,749 7,391 31,099 24,063
Interest expense (1,345 ) (943 ) (4,038 ) (2,717 )
Other income (expense), net 342 (48 ) 493 7,778
Loss before provision for income taxes (124,019 ) (92,589 ) (355,679 ) (287,319 )
Provision for income taxes 343 136 900 464
Net loss $ (124,362 ) $ (92,725 ) $ (356,579 ) $ (287,783 )
Net loss per share, basic and diluted $ (0.93 ) $ (0.74 ) $ (2.68 ) $ (2.32 )
Weighted-average shares used in computing net loss per share, basic and diluted 134,422 124,807 132,866 124,268
Guardant Health, Inc.Condensed Consolidated Balance Sheets(unaudited)(in thousands, except share and per share data)
September 30, 2026 December 31, 2025
ASSETS
Current assets:
Cash and cash equivalents $ 1,026,848 $ 378,203
Short-term marketable securities — 823,395
Accounts receivable, net 186,548 137,849
Inventory, net 93,490 85,876
Prepaid expenses and other current assets 36,519 40,723
Total current assets 1,343,405 1,466,046
Restricted cash 119,157 111,214
Property and equipment, net 151,474 145,915
Right-of-use assets 141,245 158,849
Intangible assets, net 24,988 25,921
Goodwill 77,257 77,257
Other assets, net 28,116 28,457
Total assets $ 1,885,642 $ 2,013,659
LIABILITIES AND STOCKHOLDERS’ DEFICIT
Current liabilities:
Accounts payable $ 102,512 $ 54,442
Accrued compensation 127,619 119,646
Accrued expenses 104,935 77,889
Deferred revenue 38,099 50,753
Total current liabilities 373,165 302,730
Convertible senior notes, net 1,502,413 1,504,000
Long-term operating lease liabilities 160,220 178,463
Other long-term liabilities 125,746 127,773
Total liabilities 2,161,544 2,112,966
Stockholders’ deficit:
Common stock, par value of $0.00001 per share; 350,000,000 shares authorized; 134,719,874 and 130,635,301 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively 1 1
Additional paid-in capital 3,080,321 2,900,056
Accumulated other comprehensive loss (5,133 ) (4,852 )
Accumulated deficit (3,351,091 ) (2,994,512 )
Total stockholders’ deficit (275,902 ) (99,307 )
Total liabilities and stockholders’ deficit $ 1,885,642 $ 2,013,659
Guardant Health, Inc.Supplemental Revenue Information(unaudited)(in thousands)
Three Months Ended September 30, Nine Months Ended September 30,
2026 2025 2026 2025
Oncology $ 231,264 $ 184,402 $ 655,323 $ 493,646
Biopharma and data 58,972 54,731 172,896 156,127
Screening 67,614 24,112 162,070 44,603
Licensing and other 3,125 1,951 7,329 6,379
Total revenue $ 360,975 $ 265,196 $ 997,618 $ 700,755
Reconciliation of Selected GAAP Measures to Non-GAAP Measures(unaudited)(in thousands, except per share data)
Three Months Ended September 30, Nine Months Ended September 30,
2026 2025 2026 2025
GAAP cost of revenue $ 124,822 $ 93,587 $ 345,690 $ 249,515
Amortization of intangible assets (151 ) (151 ) (449 ) (449 )
Stock-based compensation expense and related employer payroll tax expense (3,891 ) (2,564 ) (11,047 ) (7,713 )
Non-GAAP cost of revenue $ 120,780 $ 90,872 $ 334,194 $ 241,353
GAAP gross profit $ 236,153 $ 171,609 $ 651,928 $ 451,240
Amortization of intangible assets 151 151 449 449
Stock-based compensation expense and related employer payroll tax expense 3,891 2,564 11,047 7,713
Non-GAAP gross profit $ 240,195 $ 174,324 $ 663,424 $ 459,402
GAAP research and development expense $ 100,838 $ 89,957 $ 288,409 $ 265,927
Stock-based compensation expense and related employer payroll tax expense (15,896 ) (13,750 ) (46,370 ) (41,095 )
Other — (417 ) — (1,598 )
Non-GAAP research and development expense $ 84,942 $ 75,790 $ 242,039 $ 223,234
GAAP sales and marketing expense $ 177,218 $ 127,375 $ 536,304 $ 351,279
Stock-based compensation expense and related employer payroll tax expense (18,230 ) (11,451 ) (50,526 ) (33,396 )
Non-GAAP sales and marketing expense $ 158,988 $ 115,924 $ 485,778 $ 317,883
GAAP general and administrative expense $ 90,862 $ 53,266 $ 210,448 $ 150,477
Amortization of intangible assets (128 ) (236 ) (484 ) (834 )
Stock-based compensation expense and related employer payroll tax expense (28,291 ) (15,779 ) (72,642 ) (44,182 )
Other (19,000 ) (115 ) (21,400 ) (2,835 )
Non-GAAP general and administrative expense $ 43,443 $ 37,136 $ 115,922 $ 102,626
Three Months Ended September 30, Nine Months Ended September 30,
2026 2025 2026 2025
GAAP loss from operations $ (132,765 ) $ (98,989 ) $ (383,233 ) $ (316,443 )
Amortization of intangible assets 279 387 933 1,283
Stock-based compensation expense and related employer payroll tax expense 66,308 43,544 180,585 126,386
Other 19,000 532 21,400 4,433
Non-GAAP loss from operations $ (47,178 ) $ (54,526 ) $ (180,315 ) $ (184,341 )
GAAP net loss $ (124,362 ) $ (92,725 ) $ (356,579 ) $ (287,783 )
Amortization of intangible assets 279 387 933 1,283
Stock-based compensation expense and related employer payroll tax expense 66,308 43,544 180,585 126,386
Impairment of non-marketable equity securities — — — 5,000
Gain on extinguishment of convertible notes — — — (13,672 )
Other 19,000 532 21,400 4,433
Non-GAAP net loss $ (38,775 ) $ (48,262 ) $ (153,661 ) $ (164,353 )
GAAP net loss per share, basic and diluted $ (0.93 ) $ (0.74 ) $ (2.68 ) $ (2.32 )
Non-GAAP net loss per share, basic and diluted $ (0.29 ) $ (0.39 ) $ (1.16 ) $ (1.32 )
Weighted-average shares used in computing GAAP and Non-GAAP net loss per share, basic and diluted 134,422 124,807 132,866 124,268
Reconciliation of GAAP Net Loss to Adjusted EBITDA(unaudited)(in thousands)
Three Months Ended September 30, Nine Months Ended September 30,
2026 2025 2026 2025
GAAP net loss $ (124,362 ) $ (92,725 ) $ (356,579 ) $ (287,783 )
Interest income (9,749 ) (7,391 ) (31,099 ) (24,063 )
Interest expense 1,345 943 4,038 2,717
Other expense (income), net (342 ) 48 (493 ) (7,778 )
Provision for income taxes 343 136 900 464
Depreciation and amortization 10,178 9,408 29,181 29,686
Stock-based compensation expense and related employer payroll tax expense 66,308 43,544 180,585 126,386
Other 19,000 532 21,400 4,433
Adjusted EBITDA $ (37,279 ) $ (45,505 ) $ (152,067 ) $ (155,938 )
Reconciliation of Free Cash Flow to Net Cash Used in Operating Activities(unaudited)(in thousands)
Three Months Ended September 30, Nine Months Ended September 30,
2026 2025 2026 2025
Net cash used in operating activities $ (23,707 ) $ (35,413 ) $ (147,108 ) $ (158,387 )
Purchases of property and equipment (13,480 ) (10,350 ) (30,819 ) (20,458 )
Free cash flow $ (37,187 ) $ (45,763 ) $ (177,927 ) $ (178,845 )

Investor Contact:
Zarak Khurshid
[email protected]

Media Contact:
Meaghan Smith
[email protected]

Source: Guardant Health, Inc.

View All News

3100 Hanover Street
Palo Alto, CA 94303
Contact Us

Prompts

Guardant Health, Inc. (ticker GH), listed in United States.

ETFs Holding Guardant Health, Inc.

ETF Weight in ETF Shares Market value As of
HELX 9.09% 16,927 $ 2.54M Jun 30, 2026
ARKG 5.13% 651,785 $ 93.388M Nov 18, 2026
LRNZ 4.71% 13,160 $ 1.974M Jun 30, 2026
GDOC 4.02% 4,952 $ 787.467K Aug 31, 2026
LFSC 3.81% 30,287 $ 4.816M Aug 31, 2026
SPIT 3.57% 7,618 $ 1.211M Aug 31, 2026
MEDI 3.40% 9,568 $ 1.482M Nov 12, 2026
FFOX 3.11% 49,831 $ 7.476M Jun 30, 2026
FFLS 2.63% 7,152 $ 1.137M Aug 31, 2026
FRTY 2.58% 26,487 $ 3.974M Jun 30, 2026
PINK 1.99% 46,576 $ 6.673M Nov 17, 2026
FSML 1.91% 15,919 $ 2.388M Jun 30, 2026
QMOM 1.79% 47,443 $ 6.8M Nov 18, 2026
FMED 1.53% 4,975 $ 791.125K Aug 31, 2026
EHLS 1.27% 4,755 $ 684.863K Nov 17, 2026
MMSC 1.21% 4,212 $ 606.654K Nov 16, 2026
BMED 1.17% 1,166 $ 167.939K Nov 16, 2026
FFND 1.14% 7,077 $ 1.125M Aug 31, 2026
FESM 1.09% 419,091 $ 62.876M Jun 30, 2026
JSMD 1.02% 66,537 $ 10.778M Jul 31, 2026
TMSL 0.93% 167,328 $ 25.104M Jun 30, 2026
FSEG 0.89% 340 $ 51.01K Jun 30, 2026
PSC 0.87% 135,555 $ 20.337M Jun 30, 2026
JMID 0.85% 1,239 $ 200.706K Jul 31, 2026
CANC 0.66% 8,773 $ 1.395M Aug 31, 2026
MKTN 0.62% 4,416 $ 662.532K Jun 30, 2026
LSEQ 0.60% 660 $ 100.122K Nov 13, 2026
FSCC 0.56% 12,708 $ 2.021M Aug 31, 2026
FTQI 0.55% 36,602 $ 5.272M Nov 16, 2026
AFSM 0.50% 5,096 $ 733.977K Nov 16, 2026
SSMG 0.50% 98 $ 15.875K Jul 31, 2026
SEIS 0.49% 19,086 $ 2.863M Jun 30, 2026
BTAL short -0.48% -9,108 $ -1.366M Jun 30, 2026
NANC 0.46% 8,619 $ 1.241M Nov 17, 2026
RUSC 0.43% 2,294 $ 344.169K Jun 30, 2026
AFMC 0.37% 6,767 $ 974.651K Nov 16, 2026
AFGR 0.30% 1,742 $ 250.9K Nov 16, 2026
CLSE short -0.29% -16,212 $ -2.578M Aug 31, 2026
FEMG 0.28% 123 $ 18.454K Jun 30, 2026
VFMO 0.25% 30,522 $ 4.854M Aug 31, 2026
CGGR 0.23% 407,522 $ 58.695M Nov 16, 2026
JGRO 0.19% 119,368 $ 17.103M Nov 17, 2026
ESUM 0.18% 2,018 $ 326.896K Jul 31, 2026
MSSM 0.16% 7,026 $ 1.117M Aug 31, 2026
FHEQ 0.15% 8,719 $ 1.412M Jul 31, 2026
SCDS 0.13% 82 $ 11.749K Nov 17, 2026
FBCG 0.12% 51,840 $ 8.398M Jul 31, 2026
BALQ 0.11% 314 $ 45.225K Nov 16, 2026
FMDE 0.07% 36,614 $ 5.493M Jun 30, 2026
DFSU 0.07% 11,411 $ 1.767M Nov 12, 2026
AVUQ 0.03% 895 $ 128.907K Nov 16, 2026
DFUS 0.03% 41,776 $ 6.469M Nov 12, 2026
DFAU 0.03% 23,198 $ 3.592M Nov 12, 2026
FYEE 0.03% 367 $ 59.45K Jul 31, 2026
TACU 0.02% 30 $ 4,320.90 Nov 17, 2026
DCOR 0.02% 63,056 $ 9.765M Nov 12, 2026
AVLC 0.02% 2,204 $ 317.442K Nov 16, 2026
BALI 0.02% 2,549 $ 367.132K Nov 16, 2026
LCTU 0.02% 1,347 $ 194.008K Nov 16, 2026
DFAC 0.01% 84,315 $ 13.057M Nov 12, 2026
ESSC 0.01% 16 $ 2,591.84 Jul 31, 2026
FELC 0.00% 48 $ 7,201.44 Jun 30, 2026
AVSU 0.00% 29 $ 4,176.87 Nov 16, 2026